Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
AOD-9604 was advanced through Phase I and Phase II clinical trials by Metabolic Pharmaceuticals between roughly 2003 and 2007 enrolling approximately 900 participants in total
Loading dose of 5 injections within a 2 weeks period followed by one injection every 12 weeks.
BPC-157's VEGFR2 engagement provides growth factor receptor signalling, while TB-500's actin-binding properties facilitate cytoskeletal remodelling necessary for cellular motility responses
It is grouped with peptide protocols because it shares the injectable research-use format and overlaps with peptide research goals around energy, recovery, and longevity
Pain Medication: Headaches and body aches are also common after a night of drinking
US$ 28.61
US$ 29.18
US$ 29.65
US$ 21.52
US$ 22.15
US$ 28.95
US$ 25.94
US$ 21.91
US$ 22.23
US$ 24.17
US$ 28.41
US$ 29.93
